Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma (Neo Combi)
An Open Label, Single Centre, Phase II Pilot Study of Neoadjuvant Dabrafenib + Trametinib in Patients With Resectable American Joint Committee on Cancer (AJCC) Stage IIIB-C BRAF V600 Mutation Positive Melanoma
Sponsor: Melanoma Institute Australia
This PHASE2 trial investigates Melanoma and is currently ongoing. Melanoma Institute Australia leads this study, which shows 16 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
16 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE2
-
Feb 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 11 earlier versions
-
Sep 2022 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
-
Sep 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
-
Mar 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Apr 2019 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
-
Dec 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Jun 2017 [monthly]
Recruiting PHASE2
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Melanoma Institute Australia
For direct contact, visit the study record on ClinicalTrials.gov .